<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05077436</url>
  </required_header>
  <id_info>
    <org_study_id>VIT-2763-CP-103</org_study_id>
    <secondary_id>2021-003187-27</secondary_id>
    <nct_id>NCT05077436</nct_id>
  </id_info>
  <brief_title>Bioavailability Study Comparing 2 Vamifeport Oral Formulations in Fasted Versus Fed State in Healthy Subjects</brief_title>
  <official_title>A Randomised, Open-Label, Food Effect and Formulation Bioavailability Study of Two Vamifeport Oral Formulations in Healthy Male and Female Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vifor (International) Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vifor Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Two different vamifeport oral formulations will be administered in fed and fasted state to&#xD;
      assess the vamifeport food-drug interaction and to assess the relative bioavailability (the&#xD;
      proportion of drug entering the circulation) of 2 different vamifeport oral formulations in&#xD;
      healthy adult participants.&#xD;
&#xD;
      Participants will be randomly allocated to one of four treatment sequences, with four dosing&#xD;
      periods each, where different combinations of both formulations will be administered&#xD;
      following fasted and fed state.&#xD;
&#xD;
      The total study duration for each participant is up to 7 weeks and 4 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) from time 0 to the time of the last quantifiable concentration (AUC0-last) of vamifeport</measure>
    <time_frame>Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve from time 0 extrapolated to infinite time (AUC0-infinity) of vamifeport</measure>
    <time_frame>Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed concentration (Cmax) of vamifeport</measure>
    <time_frame>Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of maximum vamifeport plasma concentration (Tmax)</measure>
    <time_frame>Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal disposition phase half-life (tl/2)</measure>
    <time_frame>Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal disposition phase rate constant</measure>
    <time_frame>Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total clearance</measure>
    <time_frame>Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution during the terminal disposition phase</measure>
    <time_frame>Day 1, Day 5, Day 9, Day 13: 0-24 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a single dose of study drug, every 4 days:&#xD;
Day 1: Participants in fasted state receive Vamifeport Formulation 1&#xD;
Day 5: Participants in fed state receive Vamifeport Formulation 1&#xD;
Day 9: Participants in fed state receive Vamifeport Formulation 2&#xD;
Day 13: Participants in fasted state receive Vamifeport Formulation 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a single dose of study drug, every 4 days:&#xD;
Day 1: Participants in fed state receive Vamifeport Formulation 1&#xD;
Day 5: Participants in fasted state receive Vamifeport Formulation 2&#xD;
Day 9: Participants in fasted state receive Vamifeport Formulation 1&#xD;
Day 13: Participants in fed state receive Vamifeport Formulation 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a single dose of study drug, every 4 days:&#xD;
Day 1: Participants in fasted state receive Vamifeport Formulation 2&#xD;
Day 5: Participants in fed state receive Vamifeport Formulation 2&#xD;
Day 9: Participants in fed state receive Vamifeport Formulation 1&#xD;
Day 13: Participants in fasted state receive Vamifeport Formulation 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a single dose of study drug, every 4 days:&#xD;
Day 1: Participants in fed state receive Vamifeport Formulation 2&#xD;
Day 5: Participants in fasted state receive Vamifeport Formulation 1&#xD;
Day 9: Participants in fasted state receive Vamifeport Formulation 2&#xD;
Day 13: Participants in fed state receive Vamifeport Formulation 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vamifeport Formulation 1</intervention_name>
    <description>Vamifeport Formulation 1 is available as 60 mg oral capsules</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vamifeport Formulation 2</intervention_name>
    <description>Vamifeport Formulation 2 is available as 60 mg oral capsules</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy participant. Healthy status defined by the Investigator.&#xD;
&#xD;
          -  A body weight between 50 and 100 kg inclusive at screening.&#xD;
&#xD;
          -  Non-smokers, or former smokers.&#xD;
&#xD;
          -  Both female and male participants must agree to comply with the birth control&#xD;
             requirements for the study.&#xD;
&#xD;
          -  Ability to understand the requirements of the study and abide by the study&#xD;
             restrictions, and agreement to return for the required assessments.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of clinically significant gastrointestinal, cardiovascular, musculoskeletal,&#xD;
             endocrine, neurological, hematological, psychiatric, renal, hepatic, bronchopulmonary,&#xD;
             allergic or lipid metabolism disorders, cancer, or drug hypersensitivity.&#xD;
&#xD;
          -  Any clinically relevant abnormal 12-lead ECG finding during screening or prior to&#xD;
             randomization.&#xD;
&#xD;
          -  A clinically relevant history of drug or alcohol misuse or abuse within 2 years prior&#xD;
             to screening.&#xD;
&#xD;
          -  Positive qualitative or semi-quantitative test for drugs of abuse positive cotinine&#xD;
             screen (used to detect recent nicotine use), or alcohol breath test at screening&#xD;
             (Visit 1) or Study Day -1 (Visit 2). Use of any of these agents will be not permitted&#xD;
             during study participation.&#xD;
&#xD;
          -  Strenuous physical exercise within the 1 week prior to Visit 2/Study Day -1 admission,&#xD;
             and until completion of safety follow-up assessments are completed.&#xD;
&#xD;
          -  Female participants who are pregnant or breastfeeding.&#xD;
&#xD;
          -  Any concomitant medication (including herbal remedies and vitamins) taken within 2&#xD;
             weeks prior to Visit 2.&#xD;
&#xD;
          -  Concomitant use of hormonal contraceptives (contraception associated with inhibition&#xD;
             of ovulation), which are metabolized through cytochrome P450 (CYP) 3A4.&#xD;
&#xD;
          -  Any other investigational drug.&#xD;
&#xD;
          -  Blood draw or blood donation of ≥20 to &lt;200 ml within 2 weeks, ≥200 to &lt;400 ml within&#xD;
             4 weeks, or ≥400 ml within 12 weeks (male) or within 16 weeks (female) prior to Visit&#xD;
             2.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Szecsödy, MD</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Research Director</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>VIT-2763-CP-103 Clinical Study Team</last_name>
    <phone>+41 588 518 000</phone>
    <email>VIT2763-CP-103.study@viforpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Labcorp Clinical Research Unit Ltd.</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 20, 2021</study_first_submitted>
  <study_first_submitted_qc>September 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

